JP7008704B2 - インダニルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用 - Google Patents
インダニルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用 Download PDFInfo
- Publication number
- JP7008704B2 JP7008704B2 JP2019528544A JP2019528544A JP7008704B2 JP 7008704 B2 JP7008704 B2 JP 7008704B2 JP 2019528544 A JP2019528544 A JP 2019528544A JP 2019528544 A JP2019528544 A JP 2019528544A JP 7008704 B2 JP7008704 B2 JP 7008704B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- cycloalkyl
- replaced
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(C)(C[n]1nnc(*)n1)O Chemical compound CC(C)(C[n]1nnc(*)n1)O 0.000 description 13
- NLVVNRITLSLCDP-QMMMGPOBSA-N O[C@@H](CC1)c2c1c(Br)ccc2F Chemical compound O[C@@H](CC1)c2c1c(Br)ccc2F NLVVNRITLSLCDP-QMMMGPOBSA-N 0.000 description 2
- HSNBRDZXJMPDGH-UHFFFAOYSA-N Brc(cc1)cnc1I Chemical compound Brc(cc1)cnc1I HSNBRDZXJMPDGH-UHFFFAOYSA-N 0.000 description 1
- QYOYKFCCKGWXGH-ZETCQYMHSA-N Brc1cnc([C@H]2OC2)cc1 Chemical compound Brc1cnc([C@H]2OC2)cc1 QYOYKFCCKGWXGH-ZETCQYMHSA-N 0.000 description 1
- RDEGDIFUNMYTEN-OAHLLOKOSA-N CC(C)(C)OC(N[C@H](CCc1c(B2OC(C)(C)C(C)(C)O2)cc2)c1c2F)=O Chemical compound CC(C)(C)OC(N[C@H](CCc1c(B2OC(C)(C)C(C)(C)O2)cc2)c1c2F)=O RDEGDIFUNMYTEN-OAHLLOKOSA-N 0.000 description 1
- CWVUYKVTEPJOPL-GOSISDBHSA-N CC(C)(C)OC(N[C@H](CCc1c(cc2)-c(c(C)c3)c(C)cc3O)c1c2F)=O Chemical compound CC(C)(C)OC(N[C@H](CCc1c(cc2)-c(c(C)c3)c(C)cc3O)c1c2F)=O CWVUYKVTEPJOPL-GOSISDBHSA-N 0.000 description 1
- WLOJHBAOBFUCBS-JOCHJYFZSA-N CC(C)(C)OC(N[C@H](CCc1c(cc2)-c(c(C)c3)c(C)cc3OCCCS(C)(=O)=O)c1c2F)=O Chemical compound CC(C)(C)OC(N[C@H](CCc1c(cc2)-c(c(C)c3)c(C)cc3OCCCS(C)(=O)=O)c1c2F)=O WLOJHBAOBFUCBS-JOCHJYFZSA-N 0.000 description 1
- ILCSEFYDDJJSIQ-LLVKDONJSA-N CC(C)(C)OC(N[C@H](CCc1c(cc2)Br)c1c2F)=O Chemical compound CC(C)(C)OC(N[C@H](CCc1c(cc2)Br)c1c2F)=O ILCSEFYDDJJSIQ-LLVKDONJSA-N 0.000 description 1
- OFEKXQBRUCMTFR-SNVBAGLBSA-N CC(C)(C)[SiH-](C)(C)O[C@H]1C2(CC2)COC1 Chemical compound CC(C)(C)[SiH-](C)(C)O[C@H]1C2(CC2)COC1 OFEKXQBRUCMTFR-SNVBAGLBSA-N 0.000 description 1
- PVPOQEISXYZGNC-OPMJYIBYSA-N CC(C)(CCOc(cc1C)cc(C)c1-c(c(CC1)c2C1Nc1cnc([C@H](C3)[C@@H]3C(O)=O)cc1)ccc2F)O Chemical compound CC(C)(CCOc(cc1C)cc(C)c1-c(c(CC1)c2C1Nc1cnc([C@H](C3)[C@@H]3C(O)=O)cc1)ccc2F)O PVPOQEISXYZGNC-OPMJYIBYSA-N 0.000 description 1
- HTQRTJLNMZFEQV-LJQANCHMSA-N CC(C)(CCOc(cc1C)cc(C)c1-c(c(CC1)c2[C@@H]1N)ccc2F)O Chemical compound CC(C)(CCOc(cc1C)cc(C)c1-c(c(CC1)c2[C@@H]1N)ccc2F)O HTQRTJLNMZFEQV-LJQANCHMSA-N 0.000 description 1
- YSBLLBNPDNXAEK-IBGZPJMESA-N CC(C)(CCOc(cc1C)cc(C)c1-c(c(CC1)c2[C@H]1O)ccc2F)O Chemical compound CC(C)(CCOc(cc1C)cc(C)c1-c(c(CC1)c2[C@H]1O)ccc2F)O YSBLLBNPDNXAEK-IBGZPJMESA-N 0.000 description 1
- DWIRWLNQTVKMBT-DNKXBQEZSA-N CC(C)(CCOc(cc1C)cc(C)c1-c1cccc2c1CCC2CNc1cnc([C@@H](C2)[C@H]2C(O)=O)cc1)O Chemical compound CC(C)(CCOc(cc1C)cc(C)c1-c1cccc2c1CCC2CNc1cnc([C@@H](C2)[C@H]2C(O)=O)cc1)O DWIRWLNQTVKMBT-DNKXBQEZSA-N 0.000 description 1
- RHAVPXCHNSXYMS-PMBSFQDNSA-N CC(Cc1cnc(C(C2)[C@H]2C(O)=O)cc1)C(C)C(CC1)c2c1c(-c(cc1)ccc1-c(nc1)cnc1OC)ccc2 Chemical compound CC(Cc1cnc(C(C2)[C@H]2C(O)=O)cc1)C(C)C(CC1)c2c1c(-c(cc1)ccc1-c(nc1)cnc1OC)ccc2 RHAVPXCHNSXYMS-PMBSFQDNSA-N 0.000 description 1
- ZHEKJBCCSVNNSY-RKDXNWHRSA-N CCOC([C@H](C1)[C@@H]1c(cc1)ncc1Br)=O Chemical compound CCOC([C@H](C1)[C@@H]1c(cc1)ncc1Br)=O ZHEKJBCCSVNNSY-RKDXNWHRSA-N 0.000 description 1
- SJTPCLBPVWAFQZ-DFOFDTNNSA-N C[C@H](C(CC1)c2c1c(-c(c(C)c1)c(C)cc1OCCC(C)(C)O)ccc2)NCc1cnc([C@H](C2)[C@@H]2C(O)=O)cc1 Chemical compound C[C@H](C(CC1)c2c1c(-c(c(C)c1)c(C)cc1OCCC(C)(C)O)ccc2)NCc1cnc([C@H](C2)[C@@H]2C(O)=O)cc1 SJTPCLBPVWAFQZ-DFOFDTNNSA-N 0.000 description 1
- ZTAYPRHWOATGEM-YCIGVOEPSA-N C[C@H](C(CC1)c2c1c(-c(cc1)cc(F)c1OC)ccc2)NCc1cnc([C@H](C2)[C@@H]2C(O)=O)cc1 Chemical compound C[C@H](C(CC1)c2c1c(-c(cc1)cc(F)c1OC)ccc2)NCc1cnc([C@H](C2)[C@@H]2C(O)=O)cc1 ZTAYPRHWOATGEM-YCIGVOEPSA-N 0.000 description 1
- IELRVSHSMOMLQC-PHDIDXHHSA-N C[C@H](COC1)[C@@H]1OC Chemical compound C[C@H](COC1)[C@@H]1OC IELRVSHSMOMLQC-PHDIDXHHSA-N 0.000 description 1
- WMUWDPLTTLJNPE-UHFFFAOYSA-N Cc(cc(cc1C)O)c1Br Chemical compound Cc(cc(cc1C)O)c1Br WMUWDPLTTLJNPE-UHFFFAOYSA-N 0.000 description 1
- BCNCIMZVAMSCOG-UHFFFAOYSA-N Cc(cc(cc1C)OCCCS(C)(=O)=O)c1Br Chemical compound Cc(cc(cc1C)OCCCS(C)(=O)=O)c1Br BCNCIMZVAMSCOG-UHFFFAOYSA-N 0.000 description 1
- FULYSECTFXMAIJ-GAIPOIILSA-N Cc1cc(-c2n[n](C)nn2)cc(C)c1-c(cc1)c(CCC2Nc3cnc([C@@H](C4)[C@H]4C(O)=O)cc3)c2c1F Chemical compound Cc1cc(-c2n[n](C)nn2)cc(C)c1-c(cc1)c(CCC2Nc3cnc([C@@H](C4)[C@H]4C(O)=O)cc3)c2c1F FULYSECTFXMAIJ-GAIPOIILSA-N 0.000 description 1
- STDJAHVNNTZTAM-NZAZLUKGSA-N Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c(c1c2C(CCCc3cnc([C@@H]4[C@@H](COCO)C4)cc3)CC1)ccc2F Chemical compound Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c(c1c2C(CCCc3cnc([C@@H]4[C@@H](COCO)C4)cc3)CC1)ccc2F STDJAHVNNTZTAM-NZAZLUKGSA-N 0.000 description 1
- UBGLFZZSAXBXRK-RBCOLISLSA-N Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c(c1c2C(CNc3cnc([C@@H](C4)[C@H]4C(O)=O)cc3)CC1)ccc2F Chemical compound Cc1cc(OCCCS(C)(=O)=O)cc(C)c1-c(c1c2C(CNc3cnc([C@@H](C4)[C@H]4C(O)=O)cc3)CC1)ccc2F UBGLFZZSAXBXRK-RBCOLISLSA-N 0.000 description 1
- HZQGENLMMNOXDY-UHFFFAOYSA-N NC(CC1)c2c1c(Br)ccc2F Chemical compound NC(CC1)c2c1c(Br)ccc2F HZQGENLMMNOXDY-UHFFFAOYSA-N 0.000 description 1
- PYMYLVAGLWKDHN-UHFFFAOYSA-N O=C(CCl)c(cc1)ncc1Br Chemical compound O=C(CCl)c(cc1)ncc1Br PYMYLVAGLWKDHN-UHFFFAOYSA-N 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N O=C(c1ccccc11)NC1=O Chemical compound O=C(c1ccccc11)NC1=O XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- IADGJAPABGJTMZ-ZETCQYMHSA-N O[C@@H](CCl)c(cc1)ncc1Br Chemical compound O[C@@H](CCl)c(cc1)ncc1Br IADGJAPABGJTMZ-ZETCQYMHSA-N 0.000 description 1
- BLICXGCZBCFGDO-RXMQYKEDSA-N O[C@H]1C2(CC2)COC1 Chemical compound O[C@H]1C2(CC2)COC1 BLICXGCZBCFGDO-RXMQYKEDSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16200889.0 | 2016-11-28 | ||
| EP16200889 | 2016-11-28 | ||
| PCT/EP2017/079835 WO2018095877A1 (en) | 2016-11-28 | 2017-11-21 | Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019535792A JP2019535792A (ja) | 2019-12-12 |
| JP2019535792A5 JP2019535792A5 (https=) | 2020-12-10 |
| JP7008704B2 true JP7008704B2 (ja) | 2022-01-25 |
Family
ID=57406160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019528544A Active JP7008704B2 (ja) | 2016-11-28 | 2017-11-21 | インダニルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10125101B2 (https=) |
| EP (1) | EP3544958B1 (https=) |
| JP (1) | JP7008704B2 (https=) |
| CN (1) | CN110312706B (https=) |
| AR (1) | AR110241A1 (https=) |
| TW (1) | TW201831451A (https=) |
| WO (1) | WO2018095877A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| TWI707849B (zh) | 2018-02-13 | 2020-10-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| US12083118B2 (en) | 2018-03-29 | 2024-09-10 | Arbutus Biopharma Corporation | Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same |
| KR102591947B1 (ko) | 2018-04-19 | 2023-10-25 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| EP3820572B1 (en) | 2018-07-13 | 2023-08-16 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| JP2022552655A (ja) | 2019-10-07 | 2022-12-19 | キャリーオペ，インク． | Ｇｐｒ１１９アゴニスト |
| IL295825A (en) | 2020-02-28 | 2022-10-01 | Kallyope Inc | gpr40 agonists |
| WO2021236617A1 (en) | 2020-05-19 | 2021-11-25 | Kallyope, Inc. | Ampk activators |
| CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014524471A (ja) | 2011-08-25 | 2014-09-22 | メルク・シャープ・アンド・ドーム・コーポレーション | ピリミジンｐｄｅ１０阻害剤 |
| WO2015078802A1 (en) | 2013-11-28 | 2015-06-04 | Boehringer Ingelheim International Gmbh | New indanyloxyphenylcyclopropanecarboxylic acids |
| JP2015523339A (ja) | 2012-05-30 | 2015-08-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新しいインダニルオキシフェニルシクロプロパンカルボン酸 |
| JP2018526405A (ja) | 2015-09-09 | 2018-09-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ［｛［２，３−ジヒドロ−１Ｈ−インデン−１−イル］アミノ｝−２Ｈ，３Ｈ−フロ［３，２−ｂ］ピリジン−３−イル］酢酸、それらの医薬組成物および使用 |
| JP6816107B2 (ja) | 2015-08-07 | 2021-01-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | インダニルアミノピリジルシクロプロパンカルボン酸、医薬組成物及びこれらの使用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US628476A (en) | 1898-03-18 | 1899-07-11 | Joseph Howard Kirk | Junction of cycle, motor-car, or other frames, &c. |
| AU2003277576A1 (en) | 2002-11-08 | 2004-06-07 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
| DE102004017930A1 (de) | 2004-04-14 | 2005-11-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
| JP2008530162A (ja) | 2005-02-15 | 2008-08-07 | グラクソ グループ リミテッド | グルタミン酸受容体を増強する化合物および医薬におけるそれらの使用 |
| WO2006103503A1 (en) | 2005-03-28 | 2006-10-05 | Pfizer Japan Inc. | Substituted aryloxoethyl cyclopropanecarboxamide compounds as vr1 receptor antagonists |
| WO2007033002A1 (en) | 2005-09-14 | 2007-03-22 | Amgen Inc. | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
| JP2009530237A (ja) | 2006-03-15 | 2009-08-27 | ノイロサーチ アクティーゼルスカブ | キナゾリノン及びカリウムチャネル活性化剤としてのその使用 |
| NZ588983A (en) | 2008-06-25 | 2011-11-25 | Daiichi Sankyo Co Ltd | Carboxylic acid compound |
| WO2010051819A1 (en) | 2008-11-10 | 2010-05-14 | Neurosearch A/S | Novel 2,3-diamino-quinazolinone derivatives and their medical use |
| WO2011094890A1 (en) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
| US8642585B2 (en) | 2012-03-26 | 2014-02-04 | Boehringer Ingelheim International Gmbh | Indanyloxydihydrobenzofuranylacetic acids |
| WO2015044073A1 (en) | 2013-09-26 | 2015-04-02 | Boehringer Ingelheim International Gmbh | Process and intermediates for preparing indanyloxydihydrobenzofuranyl acetic acid derivatives as gpr40 agonists |
-
2017
- 2017-11-21 US US15/818,790 patent/US10125101B2/en active Active
- 2017-11-21 WO PCT/EP2017/079835 patent/WO2018095877A1/en not_active Ceased
- 2017-11-21 EP EP17800871.0A patent/EP3544958B1/en active Active
- 2017-11-21 CN CN201780073338.1A patent/CN110312706B/zh active Active
- 2017-11-21 JP JP2019528544A patent/JP7008704B2/ja active Active
- 2017-11-27 AR ARP170103293A patent/AR110241A1/es unknown
- 2017-11-27 TW TW106141099A patent/TW201831451A/zh unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014524471A (ja) | 2011-08-25 | 2014-09-22 | メルク・シャープ・アンド・ドーム・コーポレーション | ピリミジンｐｄｅ１０阻害剤 |
| JP2015523339A (ja) | 2012-05-30 | 2015-08-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新しいインダニルオキシフェニルシクロプロパンカルボン酸 |
| WO2015078802A1 (en) | 2013-11-28 | 2015-06-04 | Boehringer Ingelheim International Gmbh | New indanyloxyphenylcyclopropanecarboxylic acids |
| JP6816107B2 (ja) | 2015-08-07 | 2021-01-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | インダニルアミノピリジルシクロプロパンカルボン酸、医薬組成物及びこれらの使用 |
| JP2018526405A (ja) | 2015-09-09 | 2018-09-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ［｛［２，３−ジヒドロ−１Ｈ−インデン−１−イル］アミノ｝−２Ｈ，３Ｈ−フロ［３，２−ｂ］ピリジン−３−イル］酢酸、それらの医薬組成物および使用 |
Non-Patent Citations (1)
| Title |
|---|
| REGISTRY (STN) [online]，2014.05.11. [検索日 2021.08.04.]CAS登録番号 1566011-38-8 |
Also Published As
| Publication number | Publication date |
|---|---|
| TW201831451A (zh) | 2018-09-01 |
| JP2019535792A (ja) | 2019-12-12 |
| EP3544958B1 (en) | 2021-03-24 |
| AR110241A1 (es) | 2019-03-13 |
| EP3544958A1 (en) | 2019-10-02 |
| WO2018095877A1 (en) | 2018-05-31 |
| US10125101B2 (en) | 2018-11-13 |
| CN110312706A (zh) | 2019-10-08 |
| CN110312706B (zh) | 2023-08-18 |
| US20180148411A1 (en) | 2018-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7008704B2 (ja) | インダニルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用 | |
| JP6968181B2 (ja) | インダニルアミノピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用 | |
| JP7023969B2 (ja) | ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用 | |
| JP7049353B2 (ja) | 糖尿病の治療のためのインダニルアミノアザジヒドロベンゾフラニル酢酸、医薬組成物 | |
| JP7049349B2 (ja) | ベンジルアミノピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用 | |
| JP7050791B2 (ja) | ベンジルオキシピリジルシクロプロパンカルボン酸、その医薬組成物及び使用 | |
| JP7050792B2 (ja) | ベンジルオキシピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用 | |
| JP6816107B2 (ja) | インダニルアミノピリジルシクロプロパンカルボン酸、医薬組成物及びこれらの使用 | |
| JP5913752B2 (ja) | 新規インダニルオキシジヒドロベンゾフラニル酢酸 | |
| JP6163695B2 (ja) | 新しいインダニルオキシフェニルシクロプロパンカルボン酸 | |
| JP7050797B2 (ja) | ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物および使用 | |
| JP2018526405A (ja) | ［｛［２，３−ジヒドロ−１Ｈ−インデン−１−イル］アミノ｝−２Ｈ，３Ｈ−フロ［３，２−ｂ］ピリジン−３−イル］酢酸、それらの医薬組成物および使用 | |
| BR102016018535A2 (pt) | Ácidos indanilaminopiridilciclopropanocarboxílicos e composições farmacêuticas compreendendo os mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201028 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201028 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210902 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210908 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211201 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20211213 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220111 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7008704 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |